Last week was a rollercoaster for the S&P/ASX 200 Index (ASX: XJO).
Australia's benchmark index swung heavily throughout the week, ultimately finishing 2.95% lower on Friday's close than Monday's open.
Three ASX shares in particular that bounced around were:
When stocks crash and recover on a daily basis, it can be difficult for investors to pinpoint true value.
Here's what experts are saying about these ASX shares.
Image source: Getty Images
Light & Wonder
Light & Wonder shares crashed more than 7% at the start of last week. They then recovered by Thursday, before falling again on Friday.
All in all, they finished the week down 1.35%.
It's been a rough start to the year for the game developer, down 28% since the middle of January.
Holders of this ASX 200 stock will be pleased to know that analysts have a positive outlook, meaning there is the possibility of a larger recovery.
Last week, Morgans had a buy rating and $195 price target on the company.
Unlike other sectors, the broker thinks AI disruption will strengthen its competitive edge.
From Friday's closing price of $129.97, the Morgans price target indicates an upside of 50%.
Elsewhere, Bell Potter is tipping even more upside for the ASX 200 stock.
The broker has a $220 price target on Light and Wonder shares.
Domino's Pizza Enterprises
It was also a turbulent week for Domino's shares.
The ASX 200 stock initially dropped 12% before recovering significantly.
It finished the week 3.74% lower than Monday's open.
This is a snapshot of what Domino's shareholders have endured over the last year.
The share price is ultimately down 29% for the last 12 months.
Outlook is mixed amongst experts moving forward.
Morgans currently has a buy rating and $25 price target on Domino's shares.
Meanwhile, Morgan Stanley has a sell rating on Domino's Pizza shares with a target of just $15.20.
The ASX 200 company closed last week in between these targets at $19.07.
4DMedical
This ASX stock was another up-and-down company last week.
It endured heavy rises and falls but finished the week more than 13% above Monday's open.
The medical technology company is up an astounding 1000% in the last year.
Following such a run, there are now questions on valuation vs revenue.
Meanwhile, Bell Potter is optimistic that the growth can continue.
The broker set a $4.50 price target and issued a buy recommendation.
That indicates an upside of roughly 4% from last week's close.
